{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:52:42Z","timestamp":1789775562922,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016981","name":"Pharmaceutical Society of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03404"],"award-info":[{"award-number":["JP20H03404"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bbrc.2021.03.099","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T22:56:42Z","timestamp":1617058602000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Nasal\u2013subcutaneous prime\u2013boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections"],"prefix":"10.1016","volume":"554","author":[{"given":"Meito","family":"Shibuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-9221","authenticated-orcid":false,"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.03.099_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"Krammer","year":"2018","journal-title":"Influenza Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbrc.2021.03.099_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2021.03.099_bib3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.vaccine.2019.02.057","article-title":"Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza","volume":"37","author":"Sekiya","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2021.03.099_bib4","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1016\/j.vaccine.2012.10.006","article-title":"Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children","volume":"30","author":"Nakayama","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2021.03.099_bib5","doi-asserted-by":"crossref","first-page":"25ra24","DOI":"10.1126\/scitranslmed.3000759","article-title":"Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes","volume":"2","author":"Koyama","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2021.03.099_bib6","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.4049\/jimmunol.1600046","article-title":"Whole-virion influenza vaccine recalls an early burst of high-affinity memory B cell response through TLR signaling","volume":"196","author":"Onodera","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41467-020-14626-0","article-title":"Influenza A viruses are transmitted via the air from the nasal respiratory epithelium of ferrets","volume":"11","author":"Richard","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2021.03.099_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/intimm\/dxu063","article-title":"Challenges in mucosal vaccines for the control of infectious diseases","volume":"26","author":"Azegami","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/21645515.2016.1239668","article-title":"Current prospects and future challenges for nasal vaccine delivery","volume":"13","author":"Yusuf","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.bbrc.2021.03.099_bib10","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.4161\/hv.25458","article-title":"Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults","volume":"9","author":"Ainai","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.bbrc.2021.03.099_bib11","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.03.099_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/vim.2017.0022","article-title":"Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate","volume":"30","author":"Ainai","year":"2017","journal-title":"Viral Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0264-410X(95)80002-U","article-title":"Cross-protection against influenza virus infection in mice vaccinated by combined nasal\/subcutaneous administration","volume":"13","author":"Asanuma","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2021.03.099_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0264-410X(98)00048-6","article-title":"IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and\/or subcutaneous administration","volume":"16","author":"Asanuma","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.bbrc.2021.03.099_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2013.00128","article-title":"Prime-boost strategies in mucosal immunization affect local IgA production and the type of th response","volume":"4","author":"Fiorino","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2015.00430","article-title":"Characterization of the antigen-specific CD4(+) T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes","volume":"6","author":"Ciabattini","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib17","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1080\/21645515.2018.1472185","article-title":"More robust gut immune responses induced by combining intranasal and sublingual routes for prime-boost immunization","volume":"14","author":"Hwang","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.bbrc.2021.03.099_bib18","first-page":"8","article-title":"Investigating prime-pull vaccination through a combination of parenteral vaccination and intranasal boosting","author":"Roces","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.bbrc.2021.03.099_bib19","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3389\/fimmu.2019.03018","article-title":"Lipid nanoparticles potentiate CpG-oligodeoxynucleotide-based vaccine for influenza virus","volume":"10","author":"Shirai","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib20","first-page":"94","article-title":"Murine cross-reactive nonneutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice","author":"Shibuya","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e01113","article-title":"Efficient protection of mice from influenza A\/H1N1pdm09 virus challenge infection via high avidity serum antibodies induced by booster immunizations with inactivated whole virus vaccine","volume":"5","author":"Sato","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2021.03.099_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/CVI.00156-06","article-title":"Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza","volume":"13","author":"Huber","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.bbrc.2021.03.099_bib23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.bbrc.2021.03.099_bib24","doi-asserted-by":"crossref","first-page":"12406","DOI":"10.1096\/fj.202000848R","article-title":"Immunological dynamics after subcutaneous immunization with a squalene-based oil-in-water adjuvant","volume":"34","author":"Schetters","year":"2020","journal-title":"Faseb. J."},{"key":"10.1016\/j.bbrc.2021.03.099_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci. Transl. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21004952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21004952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:40:22Z","timestamp":1762094422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21004952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"alternative-id":["S0006291X21004952"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.03.099","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nasal\u2013subcutaneous prime\u2013boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.03.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}